Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders

J Med Chem. 2017 Jun 22;60(12):5193-5208. doi: 10.1021/acs.jmedchem.7b00618. Epub 2017 Jun 5.

Abstract

PI3Kδ plays an important role controlling immune cell function and has therefore been identified as a potential target for the treatment of immunological disorders. This article highlights our work toward the identification of a potent, selective, and efficacious PI3Kδ inhibitor. Through careful SAR, the successful replacement of a polar pyrazole group by a simple chloro or trifluoromethyl group led to improved Caco-2 permeability, reduced Caco-2 efflux, reduced hERG PC activity, and increased selectivity profile while maintaining potency in the CD69 hWB assay. The optimization of the aryl substitution then identified a 4'-CN group that improved the human/rodent correlation in microsomal metabolic stability. Our lead molecule is very potent in PK/PD assays and highly efficacious in a mouse collagen-induced arthritis model.

MeSH terms

  • Animals
  • Antigens, CD / metabolism
  • Antigens, Differentiation, T-Lymphocyte / metabolism
  • Arthritis, Experimental / drug therapy*
  • Caco-2 Cells / drug effects
  • Caco-2 Cells / immunology
  • Dogs
  • Drug Evaluation, Preclinical / methods*
  • ERG1 Potassium Channel / metabolism
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Humans
  • Immune System Diseases / drug therapy
  • Isoenzymes / antagonists & inhibitors
  • Isoenzymes / metabolism
  • Lectins, C-Type / metabolism
  • Male
  • Mice, Inbred BALB C
  • Phosphoinositide-3 Kinase Inhibitors*
  • Pyrazoles / chemistry
  • Pyrazoles / metabolism
  • Pyrazoles / pharmacology
  • Rabbits
  • Structure-Activity Relationship*

Substances

  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • CD69 antigen
  • ERG1 Potassium Channel
  • Enzyme Inhibitors
  • Isoenzymes
  • KCNH2 protein, human
  • Lectins, C-Type
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyrazoles